Medical management of menorrhagia

Reviews in Gynaecological Practice Pub Date : 2005-09-01 DOI:10.1016/j.rigp.2005.06.003

Amanda J. O’Leary , Harsit Tejura

{"title":"Medical management of menorrhagia","authors":"Amanda J. O’Leary , Harsit Tejura","doi":"10.1016/j.rigp.2005.06.003","DOIUrl":null,"url":null,"abstract":"<div>Menorrhagia is a common complaint and accounts for 12% of referrals to gynaecology clinics. Prevalence increases with age and peaks just prior to menopause.It has been estimated that the treatment of menorrhagia accounts for up to 1% of all healthcare costs.Effective medical treatments do exist, but clinicians are poor prescribers of the most effective treatments.The main classes of drugs employed for the medical treatment of menorrhagia are non-hormonal (inhibitors of prostaglandin synthesis, antifibrinolytic agents and haemostatic agents) and hormonal therapies.First-line management of menorrhagia consists of prostaglandin inhibitors, antifibrinolytic agents, oral contraceptive pill, high dose progestogens and progesterone intra-uterine systems, which can reduce menstrual blood loss by 25%, 50%, 50%, 85% and 90%, respectively. Second-line treatment consists of danazol and GnRH agonists which reduce menstrual loss by 50% and 100%. These treatments are second line as these use is limited by side-effects and or limited duration of use.</div>","PeriodicalId":101089,"journal":{"name":"Reviews in Gynaecological Practice","volume":"5 3","pages":"Pages 159-165"},"PeriodicalIF":0.0000,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rigp.2005.06.003","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Gynaecological Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471769705000547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Menorrhagia is a common complaint and accounts for 12% of referrals to gynaecology clinics. Prevalence increases with age and peaks just prior to menopause.

It has been estimated that the treatment of menorrhagia accounts for up to 1% of all healthcare costs.

Effective medical treatments do exist, but clinicians are poor prescribers of the most effective treatments.

The main classes of drugs employed for the medical treatment of menorrhagia are non-hormonal (inhibitors of prostaglandin synthesis, antifibrinolytic agents and haemostatic agents) and hormonal therapies.

First-line management of menorrhagia consists of prostaglandin inhibitors, antifibrinolytic agents, oral contraceptive pill, high dose progestogens and progesterone intra-uterine systems, which can reduce menstrual blood loss by 25%, 50%, 50%, 85% and 90%, respectively. Second-line treatment consists of danazol and GnRH agonists which reduce menstrual loss by 50% and 100%. These treatments are second line as these use is limited by side-effects and or limited duration of use.

查看原文本刊更多论文

月经过多的医学处理

月经过多是一种常见的抱怨，占转介到妇科诊所的12%。患病率随年龄增长而增加，在绝经前达到高峰。据估计，月经过多的治疗占所有医疗保健费用的1%。有效的药物治疗确实存在，但临床医生在最有效的治疗方法上开的处方很差。用于治疗月经过多的主要药物类别是非激素疗法(前列腺素合成抑制剂、抗纤溶剂和止血剂)和激素疗法。月经过多的一线治疗包括前列腺素抑制剂、抗纤溶药物、口服避孕药、大剂量孕激素和子宫内黄体酮系统，可分别减少月经失血量25%、50%、50%、85%和90%。二线治疗包括达那唑和GnRH激动剂，可减少月经损失50%和100%。这些治疗是二线治疗，因为它们的使用受到副作用和/或使用时间的限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reviews in Gynaecological Practice

自引率

0.00%

发文量